Guanfacine once-daily - Shire

Drug Profile

Guanfacine once-daily - Shire

Alternative Names: Guanfacine Carrier Wave; SPD 547

Latest Information Update: 14 Mar 2012

Price : $50

At a glance

  • Originator Shire
  • Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Phase I Anxiety disorders; Attention-deficit hyperactivity disorder; Autistic disorder

Most Recent Events

  • 31 Dec 2011 Phase-I development is ongoing
  • 31 Dec 2010 Phase-I clinical trials in Autistic disorder (unspecified route)
  • 31 Dec 2010 Phase-I clinical trials in Anxiety disorders in children (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top